226950.KQ实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 08:14):

OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases...

Stats
今日成交量	6 005.00
平均成交量	108 209
市值	253.85B
EPS	KRW0 ( 2024-03-15 )
下一个收益日期	( KRW0 ) 2024-05-09
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW23.20 (0.15%)

音量相关性

長: -0.14 (neutral)

短: -0.02 (neutral)

Signal:(44.97) Neutral

OliX Pharmaceuticals,Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

OliX Pharmaceuticals,Inc 相关性 - 货币/商品

0.44
( neutral )

0.23
( neutral )

0.44
( neutral )

0.45
( neutral )

0.13
( neutral )

0.06
( neutral )

OliX Pharmaceuticals,Inc 财务报表

Annual	2023
营收:	KRW17.06B
毛利润:	KRW14.42B (84.52 %)
EPS:	KRW-1 323.81

FY	2023
营收:	KRW17.06B
毛利润:	KRW14.42B (84.52 %)
EPS:	KRW-1 323.81

FY	2022
营收:	KRW9.32B
毛利润:	KRW7.35B (78.83 %)
EPS:	KRW-1 422.69

Financial Reports:

No articles found.

OliX Pharmaceuticals,Inc

OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101 for skin scar; OLX102 for skin whitening; OLX103, an atopic dermatitis product; OLX104 for hair loss; OLX105, an anti-wrinkle product; and OLX106 for diabetic foot ulcer. Its products pipeline also comprise OLX301 for age-related macular degeneration retinal fibrosis; OLX304 for retinitis pigmentosa; OLX201 for lung fibrosis; OLX202 for asthma; OLX203 for influenza; OLX401 for neuropathic pain; OLX701 for liver fibrosis; and OLX701 for cancer immunotherapy. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is based in Suwon, South Korea.